Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Axsome Therapeutics, Inc.

SG&A Expense Trends: United vs. Axsome

__timestampAxsome Therapeutics, Inc.United Therapeutics Corporation
Wednesday, January 1, 20141392830381287000
Thursday, January 1, 20152419289452612000
Friday, January 1, 20166343648316800000
Sunday, January 1, 20177206691330100000
Monday, January 1, 20189351522265800000
Tuesday, January 1, 201913598030336200000
Wednesday, January 1, 202028896749423900000
Friday, January 1, 202166646205467000000
Saturday, January 1, 2022159253661487000000
Sunday, January 1, 2023323123000477100000
Monday, January 1, 2024411359000
Loading chart...

Igniting the spark of knowledge

Navigating SG&A Expenses: A Tale of Two Biotechs

In the competitive landscape of biotechnology, effective cost management is crucial. Over the past decade, United Therapeutics Corporation and Axsome Therapeutics, Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, United Therapeutics maintained a relatively stable SG&A expense, peaking at approximately 487 million in 2022, reflecting a strategic focus on consistent operational efficiency. In contrast, Axsome Therapeutics experienced a dramatic increase, with expenses skyrocketing from a modest 1.4 million in 2014 to over 323 million by 2023, marking a staggering growth of over 23,000%. This surge highlights Axsome's aggressive expansion and investment in growth initiatives. As these companies continue to evolve, their SG&A trends offer valuable insights into their strategic priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025